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Introduction
Disorders of the blood cause some of the commonest symptoms and 
signs for which patients seek medical advice. A carefully taken history 
and meticulous physical examination, complemented by thoughtful 
and judicious use of laboratory tests, provide the clinical basis for a 
working diagnosis. Specialised haematology may be needed to extend 
evaluation to the bone marrow and plasma while supplementary 
imaging and radionuclide technology further link primary care 
practitioner or specialist to the experienced haematologist. Such a 
multidisciplinary and fully integrative approach offers the preferred 
way to problem solving and optimum management.
Under normal circumstances iron is an essential element for survival 
of plants, microbes and higher animals. Its life-sustaining properties 
play a central role in gas transfer and electron transport, catalysing 
oxidative metabolism, contri buting to cell growth, proliferation[1] and 
occupying an important role at the host-pathogen interface.[2] Body 
iron reserves are regulated by absorption at the level of the upper 
small bowel. The master regulator of these pathways is hepcidin – a 
peptide of liver origin.[3]
Any excessive accumulation in storage sites, primarily the hepatic 
parenchyma and reticuloendothelial cells, is shown by raised 
ferritin levels and percentage saturation of transferrin. The 
consequences are acceleration of free radical reactions, causing 
cellular injury and organ dysfunction which is progressive and often 
irreversible.[4] These phenomena may be primary or genetically 
determined. In contrast, secondary causes bypass the governing 
mechanism in the gastrointestinal tract, for example transfusional 
siderosis.[5] 
The classic example of iron overload syndromes are the 
haemochromatosis syndromes.[6] These are characterised by a 
distinctive increase in skin pigmentation associated with hepatic, 
pancreatic, cardiac, musculoskeletal and endocrine failure and 
specific neurological abnormalities.[7-9]
The primarily biochemical disruptions of diabetes mellitus, 
cardiovascular disease, arthritis and a range of endocrine disorders 
may also contribute to these syndromes.[10] In such situations 
diagnosis and treatment by phlebotomy to reduce excess can blunt 
subclinical tissue damage and there are data to show survival benefit, 
although reversibility in affected organs is not clearly defined. As 
a result it is important for all medical practitioners to be aware of 
haemochromatosis and its risk factors and to start treatment as early 
as possible.
Physiology
Absorption 
Dietary iron is extracted into duodenal enterocytes at the luminal 
or villous pole via the divalent metal transporter 1 (DMT 1). 
When dietary iron is digested, the metal is released and then 
converted from ferric to ferrous form. When iron is presented 
as the haem complex, transport depends upon a separate carrier 
protein (HCP 1)[3,4] (Fig. 1).
Enterocyte export 
Passage into the circulation takes place at the basal or serosal 
surface through the transmembrane structure, ferroportin, where 
function is regulated by hepcidin.[11,12] The latter peptide is produced 
by the liver and, having antimicrobial properties, is a component 
of the innate immune system. This peptide is known to be the key 
homeostatic regulator for iron. Function is modulated by other 
proteins under the control of genes for haemochromatosis (HFE) 
heamojuvelin and transferrin receptor 2.[6]
This is the third in our vignettes that are centred on everyday clinical presentations. Each emphasises practical aspects of team-based care 
that are applicable to general practitioners, specialists and paramedical professionals alike.
Iron-overload syndromes, whether genetically or environmentally determined, increase morbidity and mortality. Familial 
haemochromatosis, as the prototype, may have a prolonged subclinical phase before presenting with dermatological, hepatic, pancreatic, 
cardiac, musculoskeletal or endocrine symptoms and signs. Improved understanding of iron metabolism, coupled with genetic testing, 
underlines current approaches to screening, diagnosis and proactive multidisciplinary management encompassing appropriate family 
studies. 
These changed circumstances strongly emphasise the need for much wider appreciation of hazards associated with accumulation of this 
trace metal above physiological limits and benefits of early, or pre-emptive, correction.
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Precisely the same mechanism operates at the level of the reticulum cell 
or macrophage, allowing re-utilisation or recycling of the iron recovered 
once old red cells have been removed from circulation and degraded, 
with temporary storage in ferritin or haemosiderin (Fig. 2).[4,5] 
The ferrostat
Cellular uptake and storage are governed by the synthesis of 
transferrin and ferritin. Th ese combined processes are co-ordinated 
by the iron regulatory proteins that, when intracellular levels or 
pool are low, engage corresponding iron responsive elements in 
the transferrin receptor mRNA with up-regulation and ingress of 
iron from plasma. At the same time, retention in ferritin falls, so 
releasing more iron into the circulation, with reduced storage of 
redundant amounts both in this protein and as haemosiderin. Th e 
reverse arrangement is found when iron within cells is increased[10] 
(Fig. 3).
Transport
Internal iron kinetics
Iron is primarily transported to the developing red cell mass or 
erythron in the marrow. Delivery is via transferrin, which is the 
specialised transport protein in the plasma, to the corresponding 
receptors on the cell surface or membrane (Fig. 2). [3,4]
Smaller amounts are available for biosynthesis of metalloproteins 
or enzymes, as well as delivery to the crypts in the bowel, where 
intracellular concentrations moderate absorption. It is likely 
that both this model[3] and that focusing on hepcidin[9,11,12] function 
interactively (Fig. 1).
Pathophysiology of overload syndromes
Definition
An increase in the supply of iron to more than that required gradually 
expands stores, leading to progressive functional disturbance and 
Fig. 1. Th e major enterocyte pathways for absorption. Dietary iron in 
the bowel is reduced to the ferrous form via a reductase (1) and then 
passes into the enterocyte by the divalent metal transporter DMT1 (2). 
Haem iron is handled through a diﬀ erent carrier – HCP1 (3). Once 
within the cytoplasm (4) joins the non-haem iron pathway or handled 
as haem moving to plasma (5). Excess is stored as ferritin whereas 
that required for physiological purposes is fi rst oxidised by hephaestin 
(6) and then exported into the plasma via ferroportin (7). In contrast 
to this hepcidin model is that for crypt programming, thought to be 
operating concurrently (8).[3]
Fig. 2. Physiology of body iron exchange. Th e daily loss to the external 
environment is small, being between 1 mg and 3 mg primarily from 
desquamation of skin and gastrointestinal tract cells balanced by 
recovery from the diet. However, internal iron movement, mainly for 
haemoglobin synthesis, is up to 40 mg in 24 hours. Such rapid recycling 
through the plasma refl ects the relatively large quantities of the metal 
released from red cell breakdown in the reticuloendothelial system 
that is being transported back to developing erythroid precursors in 
the marrow. In women compensation is made for pregnancy and 
menstruation. Th e storage compartment, comprising ferritin and to a 
lesser extent haemosiderin, is located in hepatocytes and macrophages 
in liver, spleen, bone marrow as well as muscle.[6]
Fig. 3. Th e ferrostat. In contrast to cellular egress, regulated by hepcidin, 
uptake and storage are controlled by synthesis of transferrin receptors 
and ferritin. Th e latter two pathways are coordinated by a pair of 
iron-regulating proteins, designated IRP 1 and IRP 2. Th ere is up- or 
down-regulation, reciprocally via mRNA for the two proteins which 
they code, by iron-responsive elements in respective transcripts (IRE). 
Th us, when the iron pool is decreased the two options counterbalance 
in favour of reducing retention, and vice versa.[10] 
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cumulative anatomical change in target 
organs. The pattern is rate and magnitude 
dependent. Individual manifestations vary 
with genetic prevalence and penetrance.[5,7]
Classification
Primary
In primary syndromes the fault lies in the 
regulation of absorption due to mutations, 
with quantitative or qualitative defects in 
hepcidin or in other genes that determine 
unbalanced accumulation from the external 
environment, giving rise to the classic familial 
variants.[5,10]
Secondary
Secondary syndromes are  a result of lesions 
in other systems including ineffective 
erythropoiesis, chronic liver disease or 
porphyria when occurrence is sporadic.[10]
Clinical manifestations – phenotype 
Fig. 4 depicts the common clinical 
presentation of haemochromatosis.
There is some phenotypic variation with 
haemojuvelin, hepcidin or ferroportin 
mutations presenting at an earlier age. In these 
cases cardiomyopathy and endocrine defects 
are prominent. In contrast, involvement of 
haemochromatosis or the transferrin receptor 
is seen later, usually with more liver disease.[5]
Incidental diagnosis typically occurs when 
blood tests are undertaken to evaluate 
nonspecific fatigue that then reveal increases in 
ferritin or percentage saturation of transferrin.[13]
Classically, skin pigmentation occurs, typically 
called ‘bronze’, although a bluish-grey colour is 
more appropriate.[14]  
Liver function tests may be abnormal, 
whereas scleral icterus and varying degrees 
of hepatomegaly are later and more 
ominous signs, correlating with considerable 
expansion of iron stores (Fig. 5) and 
cirrhosis, progressing relentlessly to portal 
hypertension (Fig. 6).[14]
Cardiomyopathy not infrequently precedes 
clinical diagnosis. The first warning may 
be supraventricular arrhythmias that may 
be lethal. With longer duration of iron 
deposition in the myocardium restrictive 
patterns emerge, leading to symptomatic 
congestive cardiac failure as a late 
consequence.[15,16]  
There is increasing evidence that accelerated 
coronary artery disease due to atherosclerosis 
with ischaemia is a further hazard.[17]
Diabetes, which may be either type 1 
or type 2, can predate clinical diagnosis 
and should be excluded in all patients 
presenting with haemochromatosis.[18-20] 
Similarly, hypertriglyceridaemia may be 
present,[21] adding the risk of ischaemic 
damage to restrictive cardiomyopathy 
that is a result of iron accumulation in the 
myocardium.
These patients frequently have pituitary, 
thyroid or adrenocortical insufficiency. 
Fig. 4. Common clinical presentation.[14] This profile of characteristics has been altered by the 
now much wider availability and increasing use of the biochemical screening studies that bring 
to light otherwise occult or silent increases in body iron stores reflected in raised percentage of 
transferrin and increased plasma ferritin levels.[14]
Fig. 5. Liver biopsy showing cirrhosis and iron overload. There are two striking histopathological 
features on liver biopsy. The first is an increase in fibrous tissue and nodularity highlighted by 
the sirus red stain (left panel). The second is dense deposition of iron in hepatocytes revealed by 
the Perl’s reaction (right panel). (Courtesy of Dr Kathy Taylor, PathCare.)
Fig. 6. Hepatomegaly. Varying degrees of 
increasing liver size may initially be noted 
only on clinical examination. The shaded 
area is palpable hepatomegaly — this may be 
much greater, as in dotted limits. With time 
cirrhosis results in contraction, size reduces 
and may no longer be evident. It is at those 
late stages that portal hypertension occurs 
with ascites and variceal bleeding.
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Testicular atrophy is also well known. 
Careful history will reveal amenorrhoea, 
and sexual dysfunction in both sexes.[5,7,9]
Arthropathy, especially when atypical, may 
be early onset and another marker of tissue 
injury. This typically occurs in the carpal and 
metacarpal joints, particularly symmetrical 
involvement of the thumb, index and 
forefingers. Osteoporosis is common (Fig. 7).[22]
Myths abound and lead to widespread 
anxiety. It is prudent to anticipate such 
disinformation and proactively provide 
reliable reassurance for each case.[23]
Biochemical manifestations – 
genotype  
Type 1 – mutations in HFE gene
This hereditary entity is the most common 
genetic disorder in persons of Northern 
European descent, with the C282Y 
mutation being a strong predictor for 
haemochromatosis.[5,24-26] Approximately 0.44% 
of those with the disease are homozygous 
for this mutation, with around 10% 
heterozygous. Figures are for the USA and 
corresponding data for South Africa are 
not available. The H63D mutation is more 
prevalent but has a milder phenotype. 
The protein product from this gene regulates 
hepcidin expression and missense mutations 
decrease production, resulting in excess 
iron moving from the gastrointestinal tract 
into the circulation. This is most prominent 
in the homozygotes, leading to parenchymal 
deposition initially in liver but subsequently 
in the pancreas, heart and other organs. The 
same phenomenon is evident but less severe 
in the heterozygotes.[13]
Type 2 – mutations in haemojuvelin gene
This is a severe autosomal recessive 
condition, leading to early and profound 
overload with two subtypes – the first 
involving the hepcidin regulatory protein 
known as haemojuvelin. In the second the 
mutation is in the hepcidin gene itself. 
Type 3 – mutations in transferrin 
receptor 2
This is a rare autosomal defect producing 
heavy deposition in early life although it is 
less aggressive than type 2.
Type 4 – mutations in the ferroportin 
gene
This is described as atypical haemochromatosis 
and is inherited as an autosomal dominant 
condition. The normally encoded protein 
regulates enterocyte export in response to 
hepcidin, while the mutant is resistant to 
internalisation and degradation, resulting in 
unregulated iron absorption. Two subtypes 
are recognised. The first has relatively low 
transferrin saturation with deposition 
primarily in the reticuloendothelial system. 
The second resembles the traditional HFE 
phenotype targeting the hepatocyte for initial 
deposition.[27]
Non-genetic causes may reflect environmental 
injury, typically from increased dietary or 
parental sources.
Laboratory studies
Screening
Biochemically this should be selective and 
restricted to patients with unexplained 
liver disease, endocrinology or carpal 
arthropathy. It is particularly useful in first-
degree relatives of diagnosed cases.[13,18] Iron 
overload is present when serum transferrin 
saturation is initially above 45% in women 
and 50% in men.[20]
Serum ferritin levels over 300 ng/ml indicate 
increase in stores, although there is debate 
about the actual level at which studies should 
be undertaken. Targeted screening focuses on 
those with a familial history of liver disorders, 
otherwise unexplained cardiac disease, 
arthropathy or endocrinopathy, especially 
diabetes or male sexual dysfunction.[18,22]
Fig. 7. Radiological abnormalities. Severe osteoarthritic changes may occur early and are 
uniquely located in the second and third metacarpophalyngeal joints (left panel). Surprising 
degrees of skeletal demineralisation accumulate and may result in incapacitating osteoporosis 
with osteoarthritis seen in this teenager with the juvenile variant (right panel). (Courtesy of Dr 
Derek Solomon, Tuft and Partners.)
Table 1.  General management principles[32,33]
Aggressive phlebotomy – donor programme
Iron chelation as a second alternative
Essential to prevent complication – serious organ damage
Hepatocellular carcinoma
Hypogonadism – cirrhosis – destructive arthritis
Insulin-dependent diabetes
Skeletal injury
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Diagnosis
Molecular genetics is well established in 
diagnosis. The HFE mutations are typically 
C282Y and H63D, although this will vary 
geographically.[10,25]
Iron overload can be determined in selected 
patients by liver biopsy although this is 
usually limited to obtaining information 
about tissue injury such as cirrhosis. 
Less invasive alternatives are modern 
radiological techniques.[28,29] These include 
quantitative magnetic resonance imaging 
(MRI) and sophisticated research methods 
that are not readily available, such as SQUID 
or biomagnetic liver susceptometry and 
transverse magnetic relaxation rate.
General management 
principles (Table 1)
Phlebotomy 
Early diagnosis and comprehensive 
management programmes are essential 
to avoid iron-related tissue injury with 
emphasis on regular monitoring of iron 
status and the high index of suspicion for 
late-presenting complications that may 
occur despite reduction in body stores. 
Bloodletting was the treatment proposed 
in 1950. By 1969 this had become 
established as an effective means of 
improving survival. This is an inexpensive 
and readily available intervention and 
the blood can be used by the transfusion 
services.[30]
Chelation
This possibility appeared attractive but is 
inconvenient and uncomfortable for patients. 
Initially, only parenteral agents were available. 
However, new and highly effective oral 
alternatives are being evaluated both in place 
of, and in association with, venesection.[31-33]
Innovative options
An understanding of the role of low hepcidin 
levels in the pathogenesis of iron overload 
has led to research into replacement of this 
peptide. Early studies are encouraging.[34]
Reversibility 
The outlook for many of these individuals, 
particularly when diagnosed before structural 
changes such as cirrhosis have occurred, 
has continued to improve. Reduction of 
iron prevents the progression of associated 
damage to many organs and reversibility has 
been noted in diabetes. However, reversibility 
in skeletal injury is less impressive. This 
observation should be tempered with the 
realisation that long-term follow-up is 
only just becoming available and in no way 
detracts from aggressive approaches to 
reduce injurious concentrations of the trace 
metal in many tissues.
Summary and 
recommendations
Accumulating experience over the last 
five decades has clearly shown the benefits 
of early diagnosis of iron depletion and 
treatment through venesection. This 
principle remains both cost-effective and 
beneficial for the cardiovascular system 
and holds promise for atherogenesis. 
Furthermore, metabolic defects, primarily 
diabetes, undergo variable degrees of 
improvement, and replacement therapy 
for endocrinology contributes to improved 
quality and quantity of life. These diseases 
are anticipated to benefit significantly 
from more targeted therapy, for example 
of hepcidin replacement, and have been 
the model for investigating patients with 
hypertriglyceridaemia where iron overload 
may uncommonly be responsible. Finally, 
entering the era of gene therapy, and with 
the capacity to identify mutations, the 
possibility of engineering and permanent 
correction is no longer as remote as 
previously seemed to be the case.
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Single suture
Coronavirus threat
‘Can transmit from person to person’. That is how the World Health Organization is now talking of the coronavirus that emerged last 
year in the Middle East.
Clusters of people with the viral infection, dubbed Middle East respiratory syndrome (MERS), give evidence that it can spread. What’s 
more, France’s health ministry has reported that a man who fell seriously ill with MERS after a trip to Dubai passed the virus to the 
person in the next hospital bed. But the virus has not spread widely in the community and close contact appears to be necessary for 
transmission, says Keiji Fukuda of the WHO.
However, Fukuda notes that undiagnosed cases may exist, with only mild symptoms. The two earliest known cases were part of a 
cluster of respiratory infections in April 2012 in Jordan. The others were milder and are thought to have been due to the virus, even 
though standard tests were negative. Routine tests on the first French patient were also negative, only deep lung sampling uncovered 
the virus.
Virologists are now working on a test for viral antibodies that can show if someone was infected in the past. That could reveal how 
widespread the virus really is.
New Scientist, 18 May 2013
